Similar articles

• Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.

  Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ; Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group; Australasian Gastrointestinal Interest Group. Mittmann N, et al. J Natl Cancer Inst. 2009 Sep 2;101(17):1182-92. doi: 10.1093/jnci/djp232. Epub 2009 Aug 7. J Natl Cancer Inst. 2009. PMID: 19666851
• Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.

  Hoyle M, Peters J, Crathorne L, Jones-Hughes T, Cooper C, Napier M, Hyde C. Hoyle M, et al. Value Health. 2013 Mar-Apr;16(2):288-96. doi: 10.1016/j.jval.2012.11.001. Epub 2013 Jan 23. Value Health. 2013. PMID: 23538180
• Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.

  Shiroiwa T, Motoo Y, Tsutani K. Shiroiwa T, et al. Mol Diagn Ther. 2010 Dec 1;14(6):375-84. doi: 10.1007/BF03256395. Mol Diagn Ther. 2010. PMID: 21275455
• KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer.

  Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. Jimeno A, et al. Cancer J. 2009 Mar-Apr;15(2):110-3. doi: 10.1097/PPO.0b013e31819e3202. Cancer J. 2009. PMID: 19390304 Review.
• Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.

  Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. Heinemann V, et al. Cancer Treat Rev. 2009 May;35(3):262-71. doi: 10.1016/j.ctrv.2008.11.005. Epub 2008 Dec 30. Cancer Treat Rev. 2009. PMID: 19117687 Review.